{"title":"Ailanthone Suppresses Liver Cancer Cell Malignant Behavior by Regulating microRNA-489-3p","authors":"Ruiyu Guan, Yiyang Yao, Zengliang Liang","doi":"10.36468/pharmaceutical-sciences.1258","DOIUrl":null,"url":null,"abstract":"Previous literature has validated the clinical effectiveness of ailanthone in repressing the development of different human cancers. Therefore, this project aimed to investigate the role and possible mechanism of ailanthone in liver cancer. Huh-7 cells were treated with various concentrations of ailanthone (low-dose ailanthone, medium-dose ailanthone, high-dose ailanthone), or transfected with microRNA-negative control and microRNA-489-3p mimics. Furthermore, transfected Huh-7 cells were exposed with high-dose ailanthone. Cell counting kit-8, plate clone formation, scratch, and Transwell detected cell proliferation, clone formation, migration, and invasion. Besides, microRNA-489-3p, matrix metalloproteinase-2, and matrix metalloproteinase-9 contents were assessed using quantitative reverse transcription polymerase chain reaction or Western blot. After exposure to various doses of ailanthone, cell proliferation inhibition rate and microRNA-489-3p expression were increased in a dose-dependent manner, whereas cell clone formation, migration, invasive, and matrix metalloproteinase-2, matrix metalloproteinase-9 protein levels were decreased. Beyond that, microRNA-489- 3p expression was reduced in liver cancer tissues; its upregulation might block Huh-7 cell growth. MicroRNA489-3p downregulation might abrogate high-dose ailanthone-mediated cell malignant behaviors inhibition. Ailanthone treatment could hinder Huh-7 cell malignant behaviors through regulating microRNA-489-3p.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"86 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ijpsonline.com/articles/ailanthone-suppresses-liver-cancer-cell-malignant-behavior-by-regulating-microrna4893p.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmaceutical Sciences","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.36468/pharmaceutical-sciences.1258","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1
Abstract
Previous literature has validated the clinical effectiveness of ailanthone in repressing the development of different human cancers. Therefore, this project aimed to investigate the role and possible mechanism of ailanthone in liver cancer. Huh-7 cells were treated with various concentrations of ailanthone (low-dose ailanthone, medium-dose ailanthone, high-dose ailanthone), or transfected with microRNA-negative control and microRNA-489-3p mimics. Furthermore, transfected Huh-7 cells were exposed with high-dose ailanthone. Cell counting kit-8, plate clone formation, scratch, and Transwell detected cell proliferation, clone formation, migration, and invasion. Besides, microRNA-489-3p, matrix metalloproteinase-2, and matrix metalloproteinase-9 contents were assessed using quantitative reverse transcription polymerase chain reaction or Western blot. After exposure to various doses of ailanthone, cell proliferation inhibition rate and microRNA-489-3p expression were increased in a dose-dependent manner, whereas cell clone formation, migration, invasive, and matrix metalloproteinase-2, matrix metalloproteinase-9 protein levels were decreased. Beyond that, microRNA-489- 3p expression was reduced in liver cancer tissues; its upregulation might block Huh-7 cell growth. MicroRNA489-3p downregulation might abrogate high-dose ailanthone-mediated cell malignant behaviors inhibition. Ailanthone treatment could hinder Huh-7 cell malignant behaviors through regulating microRNA-489-3p.
期刊介绍:
The Indian Journal of Pharmaceutical Sciences (IJPS) is a bi-monthly Journal, which publishes original research work that contributes significantly to further the scientific knowledge in Pharmaceutical Sciences (Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Pharmacology and Therapeutics, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, Drug Information, Patient Counselling, Adverse Drug Reactions Monitoring, Medication Errors, Medication Optimization, Medication Therapy Management, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest). The Journal publishes original research work either as a Full Research Paper or as a Short Communication. Review Articles on current topics in Pharmaceutical Sciences are also considered for publication by the Journal.